Derik De Bruin
Stock Analyst at B of A Securities
(4.61)
# 203
Out of 5,057 analysts
220
Total ratings
66.89%
Success rate
15.38%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,412.18 | -1.57% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $221.20 | -0.54% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $44.70 | -39.60% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $93.40 | +17.77% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $41.79 | +19.65% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $16.35 | -20.49% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $44.65 | +18.70% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $379.30 | -1.13% | 14 | Jun 26, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $146.89 | -12.86% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $6.35 | +73.23% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $67.75 | -4.06% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $10.01 | +59.84% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $580.13 | +13.77% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $223.55 | +5.12% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $169.21 | +24.11% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $266.66 | +33.13% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $22.65 | +14.82% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $267.87 | +1.17% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $187.58 | -2.97% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $10.22 | +105.48% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $17.20 | +86.05% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $119.93 | -16.62% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.26 | +15.81% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.17 | +310.09% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.04 | +218.63% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $163.45 | +59.07% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $8.00 | +1,400.00% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $121.16 | -0.96% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.16 | +316.67% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $701.48 | -66.50% | 3 | Nov 2, 2018 |
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,412.18
Upside: -1.57%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $221.20
Upside: -0.54%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $44.70
Upside: -39.60%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $93.40
Upside: +17.77%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $41.79
Upside: +19.65%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $16.35
Upside: -20.49%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $44.65
Upside: +18.70%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $379.30
Upside: -1.13%
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $146.89
Upside: -12.86%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $6.35
Upside: +73.23%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $67.75
Upside: -4.06%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $10.01
Upside: +59.84%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $580.13
Upside: +13.77%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $223.55
Upside: +5.12%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $169.21
Upside: +24.11%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $266.66
Upside: +33.13%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.65
Upside: +14.82%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $267.87
Upside: +1.17%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $187.58
Upside: -2.97%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $10.22
Upside: +105.48%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $17.20
Upside: +86.05%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $119.93
Upside: -16.62%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.26
Upside: +15.81%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.17
Upside: +310.09%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.04
Upside: +218.63%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $163.45
Upside: +59.07%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $8.00
Upside: +1,400.00%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $121.16
Upside: -0.96%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.16
Upside: +316.67%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $701.48
Upside: -66.50%